VIVITROL AND COUNSELING:
PROVEN TO PREVENT RELAPSES
More patients achieved complete abstinence* with VIVITROL and counseling than with placebo1,2
45 out of 126 patients treated with VIVITROL had complete abstinence compared to 28 out of 124 patients treated with placebo
Patients were less likely to relapse to dependence2,3
Only 1 patient discontinued due to relapse compared to 17 patients on placebo
94% fewer relapses to dependence with VIVITROL
Patients had a significant reduction in opioid cravings2
Patients treated with VIVITROL and counseling experienced a decrease in craving, while patients who received placebo had an increased craving for opioids‡
Patients treated with VIVITROL experienced an average decrease in craving score of 10.1 from 18.2
Patients treated with placebo experienced an average increase in craving score of 0.7 from 21.8
This data is from a 6-month, double-blind, placebo-controlled, randomized clinical study of 124 opioid-dependent patients treated with placebo and counseling who were compared to 126 opioid-dependent patients treated with VIVITROL and counseling, following opioid detoxification.1,2
IVITROL IS AN OPIOID ANTAGONIST OR BLOCKING MEDICATION1-3
Antagonists create a barrier that blocks opioid molecules from attaching to opioid receptors. Antagonists attach to opioid receptors, but do not cause the release of dopamine. They are non-addictive and do not lead to physical dependence. VIVITROL blocks opioid receptors for one month at a time. Patients must be opioid-free before starting VIVITROL.
VIVITROL is an antagonist that blocks opioid molecules from attaching to opioid receptors.
VIVITROL is not right for everyone. There are significant risks from VIVITROL treatment, including risk of opioid overdose, severe reaction at the injection site and sudden opioid withdrawal.
See Important Safety Information below. Discuss all benefits and risks with a healthcare provider.
Dr. Natasha Fuksina is an official provider of VIVITROL.